Skip to content
The Future Explorerby Benjamin Talin
Enablertechnological

Synthetic Biology

Designing and building living systems that do not exist in nature, such as microbes rewritten to brew a useful substance the way yeast brews beer. The enzyme that curdles milk into most of today's cheese has been made by engineered microbes for more than thirty years. Doing the same for everyday chemicals has proved much harder: a company that promised exactly that went bankrupt. Design is fast; building, testing and making it pay are slow.

Maturity

2/ 5
measured
BasisDesign is fast and getting faster; building and testing are not, and the National Academies say so plainly. Commercially it is real in a few high-value ingredients and unproven at commodity scale - the sector's two flagships produced a bankruptcy and a shrinking revenue line.SourceE-143 (NASEM, The Age of AI in the Life Sciences, 23 Apr 2025); Amyris 8-K (9 Aug 2023, Ch.11, D. Del. Case No. 23-11131); Ginkgo Bioworks FY2025 results (26 Feb 2026); FDA 21 CFR 184.1685 (55 FR 10935, 23 Mar 1990); HHS synthetic nucleic acid screening guidance (13 Oct 2023)Vintage1990–2026
ReadinessCapability 3Deployment 2Absorption 2Bound bycapitalTrendflat

Where it feeds in

4 megatrends in 2 forcesweakest link

Where you have already met this

The enzyme that curdles most cheese is made by engineered microbes. The US regulator affirmed it as safe on 23 March 1990, and it has been in the vat ever since. Thirty-three years later the company that promised the same trick for industrial chemicals filed for bankruptcy in Delaware. The fermenter worked. The economics did not.

If this moved

If fermentation capacity could be built and run at costs that beat the petrochemical route, materials substitution and food-system change would each lose an input. Neither reading would move: consumption norms hold both at 1. The one it could shift is zoonotic and antimicrobial-resistance risk, where it is one of the two enablers setting the reading.

What to watch for

Contract fermentation capacity that runs at a profit without venture money behind it - company filings show that before any announcement does. Whether screening of synthesised DNA becomes a condition of sale rather than voluntary guidance.

Not to be confused with

Gene editing. Editing changes something already in an organism; this writes sequences and pathways from a design, which is why the biosecurity questions are different ones.

What it is

Designing and building biological systems that do not exist in nature - engineered organisms, synthetic chromosomes and designed proteins.

How it works

  1. 01A sequence is designed, increasingly by softwareModels propose protein structures and pathways that do the job you specify. This is the step that has got dramatically faster.
  2. 02DNA is synthesised to that designMachines assemble the sequence chemically. This is also the step where biosecurity screening, where it happens, happens.
  3. 03The construct goes into a host organismA yeast, bacterium or fungus is given the new genes and becomes the factory. The host is called the chassis, and its quirks decide how well anything works.
  4. 04The organism is grown in a tankFermenters feed the culture sugar and oxygen under controlled conditions. Performance at ten litres tells you surprisingly little about performance at a hundred thousand.
  5. 05The product is separated outCells are broken, spun and the target molecule purified. For low-value products this step, not the biology, decides the cost.
  6. 06Scale-up is where it usually stopsCapacity costs like a chemical plant and has to beat a chemical plant on price. That is the wall the sector's flagships hit.

State of play

  • The National Academies found AI's uplift is 'in the ideation and design phases' and that these tools 'do not necessarily reduce the bottlenecks and barriers to crossing the digital–physical divide' (NASEM, The Age of AI in the Life Sciences, 23 Apr 2025).
  • The same report concluded that no available AI-enabled biological tool can design a virus de novo, and that AI-assisted toxin design would likely be 'limited to the local level rather than elevated to an epidemic or pandemic level' (NASEM, 23 Apr 2025).
  • The FDA affirmed fermentation-derived chymosin from engineered E. coli K-12 as generally recognised as safe on 23 March 1990 (Federal Register 55 FR 10935; 21 CFR 184.1685).
  • Amyris, one of the sector's flagship scale-up attempts, filed for Chapter 11 on 9 August 2023 in the District of Delaware (Amyris Form 8-K, Aug 2023).
  • Ginkgo Bioworks' revenue fell from $251 million in 2023 to $227 million in 2024 and $170 million in 2025, with a net loss of $313 million in 2025 (Ginkgo Bioworks, FY2025 results, 26 Feb 2026).
  • US screening of synthetic nucleic acid orders against sequences of concern runs on voluntary guidance, published on 13 October 2023 and replacing the 2010 framework (Federal Register, 13 Oct 2023).

Why it matters

It treats biology as a manufacturing platform. Where it works, it substitutes biological production for chemical or extractive production, which changes supply chains rather than efficiency.

  • Food system transformation and circular economy both sit at 1, held by consumption norms. Nothing this enabler does moves either; what it changes is where a material comes from, not whether anyone wants it.
  • It is one of the two enablers setting zoonotic and antimicrobial-resistance risk at 2, alongside epistemic trust - and it is the half that is getting cheaper and more widely available.
  • It is the cleanest case in the book of a design step outrunning a manufacturing step. Writing the sequence is nearly free. The tank is not.

What holds it back

Capital for tanks

Commercial fermentation capacity is built like a chemical plant, and it has to undercut one. That is a capital decision made against petrochemical prices.

Scale-up risk

A strain that performs in a small vessel routinely under-performs in a large one. The money is committed before that is known.

Purification cost

For anything low-value, separating the product out costs more than making it.

Biosecurity screening is voluntary

US screening of ordered sequences rests on guidance, not regulation, and applies to the providers who choose to follow it.

Approval product by product

Anything eaten or released needs its own regulatory pathway, in each jurisdiction.

Terms

Precision fermentation
Growing engineered microbes in a tank to make one specific molecule - an enzyme, a protein, a fat.
Host chassis
The organism the new genetic instructions are put into; it supplies the machinery that does the work.
Design–build–test–learn
The engineering loop of this field: propose a sequence, make it, measure it, feed the result back into the next design.
Sequence of concern
A synthesised DNA sequence matching a regulated pathogen or toxin, which screening is meant to catch before it is shipped.
Scale-up
Moving a process from laboratory volumes to industrial ones - where most of this sector's failures happen.

Steepens

MegatrendWeightRole
Food System Transformationmoderate
Circular Economy and Materials Substitutionmoderate
Zoonotic and Antimicrobial Resistance Riskmoderateshared weakest link (with 1 other)
Critical Mineral and Resource Scarcitymarginalmarginal: not counted as a weakest link

The gradient behaves like a sticky rubber band: it is pulled hardest toward the weakest enabler. Marginal links are shown but do not pull.

If this moved one step

Computed from the map as it stands: this score raised from 2 to 3, every other score unchanged. It is arithmetic, not a forecast.

Raised one step on its own, it lifts no megatrend's weakest link; each gradient it feeds still rises a little.

Tied as the weakest link

Here it shares the weakest spot with other enablers. Raising it alone leaves the weakest link where it is and lifts the gradient a little; the enablers it is tied with must move too.

The gradient also rises in

What if it moved?

What would change the gradient

Conditional, not predictive. No dates, no probabilities.

  1. 01Fermentation scale-up capacity, which is a capital-intensive bottleneck
  2. 02Biosecurity governance keeping pace with diffusing capability
  3. 03Feedstock cost, which determines whether biological production competes

Common misconception

That it is an extension of gene editing. Editing modifies what exists; this builds what does not, and the design, biosecurity and scale-up questions are correspondingly different.

Talin, B. (2026). Synthetic Biology. The Future Explorer, dataset v0.4.0 (2026-11-16). https://explorer.talin.digital/e/synthetic-biology/